Auxi Therapeutics

Auxi Therapeutics is a biotechnology company focused on improving the outcomes of hematopoietic stem cell (HSC) transplantation for patients with hematologic malignancies and other blood disorders. The company's proprietary platform technology enables the ex vivo expansion of CD34+ hematopoietic stem cells, specifically addressing the limitations of low cell counts in umbilical cord blood units. By increasing the dose of functional stem cells while preserving their engraftment potential, Auxi aims to accelerate neutrophil and platelet recovery and reduce the risk of infection and transplant-related mortality. This approach has the potential to make cord blood transplantation a more viable and safer option for a broader range of patients. Headquartered in Madison, Wisconsin, the company is a spin-out from the University of Wisconsin-Madison.